Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06290141 · ClinicalTrials.gov registry record · Phase 3
A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
A Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT06290141: Recruiting Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, sponsored by Sanofi.
NCT06290141 is a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy that is actively recruiting participants, run by Sanofi. The registered enrollment target is 160 participants, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (10% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06290141, a Phase 3 study of Chronic Inflammatory Demyelinating Polyneuropathy, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
Primary Outcome
A response is defined as decrease of ≥1 point from baseline in adjusted INCAT disability score at Week 24
Conditions Studied
Interventions
- DRUG Placebo
- DRUG riliprubart
- DRUG IVIg
Study Locations (20)
New York
- Dent Neurologic Institute - Amherst- Site Number : 8400039 - Amherst
- Hospital for Special Surgery- Site Number : 8400041 - New York
- Columbia University Irving Medical Center- Site Number : 8400003 - New York
California
- Keck School of Medicine of University of Southern California- Site Number : 8400002 - Los Angeles
- University of California Irvine Medical Center- Site Number : 8400007 - Orange
Florida
- AdventHealth Orlando- Site Number : 8400006 - Orlando
- AdventHealth Site Number : 8400006 - Orlando
Michigan
- Henry Ford Hospital- Site Number : 8400025 - Detroit
- Michigan State University- Site Number : 8400038 - East Lansing
Ohio
- University of Cincinnati Medical Center- Site Number : 8400020 - Cincinnati
- University Hospitals Cleveland Medical Center- Site Number : 8400033 - Cleveland
Alabama
- Alabama Neurology Associates- Site Number : 8400019 - Homewood
Arizona
- Honor Health Scottsdale Osborn Medical Center- Site Number : 8400014 - Scottsdale
Connecticut
- Yale University School of Medicine- Site Number : 8400018 - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2024-08-21 |
| Est. Completion | 2029-01-12 |
| Phase | Phase 3 |
What NCT06290141 shows while recruiting
NCT06290141 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, above the 146-participant average among 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials with a reported enrollment target (10% higher).
The record links to 1 condition, with Chronic Inflammatory Demyelinating Polyneuropathy appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06290141 names 20 study sites across 14 states, led by New York, California, Florida.
Frequently Asked Questions
What is clinical trial NCT06290141 about?
NCT06290141 is a clinical study titled "A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)". The purpose of the study is to evaluate efficacy of riliprubart compared to IVIg in adult participants with CIDP who are receiving maintenance treatment with IVIg. The study duration will be for a maximum of 109 weeks including screening, treatment phases, and follow-up.
What is the current status of trial NCT06290141?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2024-08-21. Estimated completion is 2029-01-12.
What conditions does trial NCT06290141 study?
This clinical trial studies the following conditions: Chronic Inflammatory Demyelinating Polyneuropathy.
What interventions are being tested in trial NCT06290141?
The interventions under investigation include: Placebo (DRUG), riliprubart (DRUG), IVIg (DRUG).
Who is sponsoring clinical trial NCT06290141?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06290141 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Inflammatory Demyelinating Polyneuropathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06290141's enrollment target sits among peer trials
160 6th of 11 higher than 5 of 11 other Chronic Inflammatory Demyelinating Polyneuropathy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Inflammatory Demyelinating Polyneuropathy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)
RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP
RECRUITING · Phase 3
-
A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP
RECRUITING · Phase 3
-
IVIG vs SCIG in CIDP
RECRUITING · Phase 1
-
Safety, Tolerability, and Efficacy of NVG-2089 in Participants With CIDP
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI